Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1677-1685

  Zhao, Qi ^a   Feng, Yang ^a   Zhu, Zhongyu ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; INSULIN; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M708.2; MONOCLONAL ANTIBODY M708.5; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; DRUG RECEPTOR BINDING; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SINGLE-CHAIN ANTIBODIES;

EID: 80052716613     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0281     Document Type: Article

References (37)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
2. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2007;96 Suppl:R7-10.
3. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005;205:145-53. (Pubitemid 40227987)
4. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47. (Pubitemid 46220849)
5. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2002;2:191-207.
6. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005;10:1041-7. (Pubitemid 41074142)
7. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010;62:199-236.
8. Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L, LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem 1995;270:29176-81.
9. Feng Y, Dimitrov DS. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 2008;11:178-85. (Pubitemid 351281057)
10. Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 2009;8:2110-21.
11. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006;5:114-20.
12. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994;54:4848-50. (Pubitemid 24289413)
13. Wang Y, Lipari P, Wang X, Hailey J, Liang L, Ramos R, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 2010;9:410-8.
14. Zhang MY, Feng Y, Wang Y, Dimitrov DS. Characterization of a chimeric monoclonal antibody against the insulin-like growth factor-I receptor. MAbs 2009;1:475-80.
15. Su JL, Stimpson S, Edwards C, Van Arnold J, Burgess S, Lin P. Neutralizing IGF-1 monoclonal antibody with cross-species reactivity. Hybridoma 1997;16:513-8. (Pubitemid 28034572)
16. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, et al. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 2010;9:1809-19.
17. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7:2575-88.
18. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
19. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71.
20. Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004;64:6252-8. (Pubitemid 39129428)
21. Miyamoto S, Nakamura M, Shitara K, Nakamura K, Ohki Y, Ishii G, et al. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 2005;11:3494-502. (Pubitemid 40627904)
22. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011;71:1029-40.
23. Zhu Z, Dimitrov DS. Construction of a large naive human phage-displayed Fab library through one-step cloning. Methods Mol Biol 2009;525:129-42, xv.
24. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006;1:755-68.
25. Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel 2010;23:155-9.
26. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 2000;97:10701-5.
27. Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 2000;328:430-44.
28. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007;25:107-16. (Pubitemid 46087909)
29. Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009;8:1113-8.
30. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 2007;104:12123-8. (Pubitemid 47185640)
31. Zhao Q, Chan YW, Lee SS, Cheung WT. One-step expression and purification of single-chain variable antibody fragment using an improved hexahistidine tag phagemid vector. Protein Expr Purif 2009;68:190-5.
32. Hackel BJ, Kapila A, Wittrup KD. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 2008;381:1238-52.
33. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 2008;197:846-53. (Pubitemid 351417007)
34. Blaise L, Wehnert A, Steukers MP, Van den Beucken T, Hoogenboom HR, Hufton SE. Construction and diversification of yeast cell surface displayed libraries by yeast mating: application to the affinity maturation of Fab antibody fragments. Gene 2004;342:211-8. (Pubitemid 39452340)
35. Yeung YA, Wittrup KD. Quantitative screening of yeast surface-displayed polypeptide libraries by magnetic bead capture. Biotechnol Prog 2002;18:212-20. (Pubitemid 34294228)
36. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37. (Pubitemid 36588961)
37. Kimura T, Kuwata T, Ashimine S, Yamazaki M, Yamauchi C, Nagai K, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010;16:121-9.